CY-09
CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation[1].
Product Specifications
CAS Number
1073612-91-5
UNSPSC
12352005
Hazard Statement
H302
Target
NOD-like Receptor (NLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/CY-09.html
Purity
99.58
Solubility
DMSO : ≥ 150 mg/mL|H2O : < 0.1 mg/mL
Smiles
OC(C1=CC=C(/C=C2SC(N(CC3=CC=CC(C(F)(F)F)=C3)C\2=O)=S)C=C1)=O
Molecular Formula
C19H12F3NO3S2
Molecular Weight
423.43
Precautions
H302
References & Citations
[1]Jiang H, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017 Nov 6;214 (11) :3219-3238.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
NLRP3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC471198-500 1x 500 µL
Cytokeratin 7 (KRT7/1198), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
